Justin Taylor, MD, discusses the rationale for an ongoing phase II trial that is exploring the combination of vemurafenib, a BRAF inhibitor, plus the anti-CD20 monoclonal antibody obinutuzumab in previously untreated patients with classical hairy cell leukemia.
Justin Taylor, MD, attending physician at Memorial Sloan Kettering Cancer Center (MSKCC), discusses the rationale for an ongoing phase II trial (NCT03410875) that is exploring the combination of vemurafenib (Zelboraf), a BRAF inhibitor, plus the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) in previously untreated patients with classical hairy cell leukemia.
This is the first trial to look at targeted therapies in the frontline for treatment of patients with hairy cell leukemia, Taylor says. At MSKCC and the University of Perugia in Italy, vemurafenib was evaluated in a phase II study in the relapsed setting for this patient population. The data from that trial suggested good response rates with the targeted agent, Taylor explains, which led to the rationale for this ongoing trial.
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More